Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in Relapsed SCLC with HR Pathway Mutations (SUKSES-B)
NCT03009682Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Aug 2016
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in small cell lung cancer (SCLC), sponsored by Samsung Medical Center. Started Aug 2016; status: completed.
02
Drugs
olaparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03009682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03009682.